Compugen this week introduced the Viral Peptides Discovery Platform for the identification of peptides from viral genomes for potential therapeutic use against inflammatory and immune-related diseases.
The company said the platform has been validated and led to the discovery of two novel viral peptides that have demonstrated the ability to suppress inflammatory response in in vitro studies.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
